Welcome to our dedicated page for EUDA Health Holdings SEC filings (Ticker: EUDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
EUDA’s blend of AI software, licensed clinics and cross-border telemedicine means its SEC disclosures read like both a tech prospectus and a medical-compliance manual. Sifting through dozens of forms to locate telehealth revenue, wellness-product margins or patient-data risk factors can overwhelm even seasoned analysts.
Stock Titan solves that problem. Our AI-powered analysis turns every EUDA SEC document—whether it’s a 20-F annual report, a 6-K interim update, or an 8-K material event filing—into clear takeaways you can act on. Need the latest EUDA quarterly earnings report 10-Q filing? We tag the KPIs and compare them to prior quarters. Tracking management moves? Receive instant alerts on EUDA insider trading Form 4 transactions plus a plain-English summary. Each filing lands here the moment EDGAR posts it, complete with side-by-side financial tables, keyword search and context from industry peers.
What can you uncover?
- Segment performance across Medical Services vs. Property Management—without wading through 300 pages.
- Revenue impact from EUDA’s Malaysian holistic-wellness acquisition, highlighted in the EUDA 8-K material events explained section.
- Executive pay details inside the EUDA proxy statement executive compensation filings.
- Real-time EUDA Form 4 insider transactions to gauge management’s confidence.
Whether you’re trying to understand EUDA SEC documents with AI, compare patient-volume trends, or review an EUDA annual report 10-K simplified, this page keeps every disclosure in one place—analyzed, summarized and ready for decision-making.
EUDA Health Holdings Limited has filed a prospectus supplement to end its continuous offering of Convertible Promissory Notes and the Ordinary Shares issuable upon their conversion under a prior prospectus. The company had the ability to issue up to US$10,000,000 of Convertible Notes and previously registered up to 5,000,000 Ordinary Shares for issuance upon conversion; as of this supplement it has sold Convertible Notes with an aggregate principal amount of $1,000,000 and issued 692,729 Ordinary Shares to the investor upon conversion. No additional Convertible Notes will be sold and no further shares will be issued under that note program. Separately, EUDA maintains a shelf registration allowing it to offer up to $100,000,000 of ordinary shares, warrants, subscription rights, debt securities and units over time. The filing also highlights the $15.0 million share-based acquisition of CK Health, for which EUDA issued 8,571,428 shares and later recognized a $14,762,562 impairment on related intangible assets, and notes that a significant shareholder holds demand registration rights for the 8,571,428 shares.
EUDA Health Holdings Limited reports that the investor in its August 2025 convertible note has agreed to convert the remaining $162,500 balance of the note into 81,250 ordinary shares. This completes conversion of the initial $1,000,000 August Note, of which $837,500 had already been converted into 569,859 shares before September 19, 2025. In addition, the investor previously received 41,620 shares at a conversion price of $0.901 per share under related letter agreements. The company also states that it does not intend to send any further put requests for additional notes under the original up to $10,000,000 purchase agreement.
EUDA Health Holdings announced a board change. Independent director Prof. Wong Kong Yew resigned effective October 23, 2025, including his roles as Chairman of the Compensation Committee and member of the Audit and Nomination Committees. The company stated his resignation was not due to any disagreement or dispute with the company or its Board.
On October 24, 2025, the Board appointed Huang Bo as an independent director, Chairman of the Compensation Committee, and member of the Audit and Nomination Committees. The Board determined Mr. Huang is independent under Nasdaq rules and Rule 10A-3. It reviewed his role at entities linked to a EUDA business partner and concluded this would not interfere with his independent judgment. The company also noted there are no related-party transactions involving Mr. Huang requiring disclosure.
EUDA Health Holdings Ltd amended its annual report describing continued operating losses, a May 8, 2024 acquisition of CK Health Plus Sdn Bhd and significant non-cash impairment charges. The Company reported 37,153,049 ordinary shares outstanding as of December 31, 2024 and recorded a $14,755,560 impairment of intangible assets in 2024.
Management disclosed substantial doubt about the Company’s ability to continue as a going concern within one year, noting recurring losses since 2020, cash of approximately $0.2 million and a need to raise additional financing. The CK Health acquisition was settled with 8,571,428 newly issued shares valued at $15.0 million (at $1.75 per share), plus a contingent 1,000,000-share earnout tied to 2024–2025 net income milestones.
FAQ
What is the current stock price of EUDA Health Holdings (EUDA)?
What is the market cap of EUDA Health Holdings (EUDA)?
